Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Botox Coverage & Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0238

    Botox (onabotulinumtoxinA) — Coverage Criteria

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0238 alerts

    Get alerted when Policy IC-0238 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Viva Health prior-authorization, dosing limits, and medical necessity criteria for onabotulinumtoxinA (Botox) for multiple indications across intramuscular, intradetrusor, and intradermal uses; applies to providers requesting coverage for members.

    Policy Summary
    PayerViva Health
    PolicyBotox (onabotulinumtoxinA) — Coverage Criteria
    Policy CodePolicy IC-0238
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization specifying HCPCS J0585 units, document indication-specific dosing and objective baseline/response measures, and ensure absence of contraindications before administration.
    SourceLink
    6 monthsinitial prior authorization validity
    12 monthsrenewal prior authorization validity
    400max cumulative dose (adult/12w)
    J0585HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 wks
    re-treatment interval (typical)
    Appendix ANQTL appendix

    Coverage and Medical Necessity Criteria

    Prior authorizations for onabotulinumtoxinA are time-limited and subject to renewal requirements. Initial authorizations are issued for 6 months (180 days), and, unless otherwise specified, subsequent renewals may be approved for 12 months (365 days) when the member continues to meet universal and indication‑specific criteria and the duration of authorization has not been exceeded.

    Some indications have different renewal timing (for example, strabismus, esophageal achalasia, temporomandibular disorders, and chronic anal fissures are noted as renewable every 6 months (180 days)), and preoperative use for ventral hernia is explicitly non‑renewable.

    Renewal is excluded when there is evidence of unacceptable toxicity attributable to the drug. Examples of unacceptable toxicity cited include symptoms consistent with toxin spread (e.g., generalized muscle weakness, dysphagia, dysphonia), severe hypersensitivity reactions (anaphylaxis, serum sickness, angioedema), severe pulmonary effects, corneal exposure/ulceration, autonomic dysreflexia, urinary complications (UTI, retention), and other clinically significant adverse events. Renewal will also not be approved if the original authorization duration has been exceeded or other renewal conditions are not met.

    Units of onabotulinumtoxinA (Botox) are assay‑ and preparation‑specific and are not interchangeable with units of other botulinum toxin products; conversion between products is not permitted. Providers must bill using Botox units as defined by the product and follow the policy's per‑indication unit limits.

    Within the excerpted policy material there are no additional explicit exclusion lists beyond the indication‑specific and universal contraindications already described. Appendix A (the NQTL checklist) and the main policy text provide the basis for prior authorization application rather than enumerating other standalone exclusions in these chunks.

    Coverage and renewal are contingent on adherence to dosing and timing limits. Administration that would cause cumulative dosing to exceed stated caps (e.g., > 400 Units per 12 weeks in adults or pediatric limits of the lower of 10 U/kg or 340 Units per 12 weeks) or that occurs before the minimum re‑treatment interval (typically 12 weeks unless an indication specifies otherwise) may be limited or denied.

    In the provided chunks there are no standalone statements labeled as ‘not medically necessary.’ Instead, the policy frames coverage limits through specific dosing, interval, and renewal criteria. The policy notes that administrations exceeding cumulative dose limits or before minimum re‑treatment intervals would not meet the dosing criteria in this section, which functions as the operational standard for medical necessity determinations.

    Billing Codes, Units, and Diagnosis Codes

    Max Units by indication (HCPCS unit)HCPCS
    BlepharospasmBillable Units = 200; Per # days = 84
    Cervical DystoniaBillable Units = 300; Per # days = 84
    StrabismusBillable Units = 100; Per # days = 84
    Esophageal AchalasiaBillable Units = 100; Per # days = 168
    Upper Limb SpasticityBillable Units = 400; Per # days = 84
    Lower Limb SpasticityBillable Units = 400; Per # days = 84
    Chronic MigraineBillable Units = 200; Per # days = 84
    Severe Primary Axillary HyperhidrosisBillable Units = 100; Per # days = 112
    SialorrheaBillable Units = 100; Per # days = 84
    Neurogenic Bladder/Detrusor OveractivityBillable Units = 200; Per # days = 84
    1–10 of 19
    1/2
    Covered HCPCS CodesHCPCSCovered
    J0585Injection, onabotulinumtoxin A, 1 unit; 1 billable unit = 1 unit
    Available NDCsNDC
    00023-1145-xxBotox 100 unit powder for injection; single-dose vial
    00023-3921-xxBotox 200 unit powder for injection; single-dose vial
    Covered ICD-10 Codes (partial list)ICD-10Covered
    G11.4Hereditary spastic paraplegia.
    G24.3Spasmodic torticollis.
    G24.4Idiopathic orofacial dystonia.
    G24.5Blepharospasm.
    G24.8Other dystonia.
    G24.9Dystonia, unspecified.
    G25.89Other specified extrapyramidal and movement disorders.
    G35.ARelapsing-remitting multiple sclerosis.
    G35.B0Primary progressive multiple sclerosis, unspecified.
    G35.B1Active primary progressive multiple sclerosis.
    1–10 of 26
    1/3
    Covered ICD-10 Codes (continued)ICD-10Covered
    G51.32Clonic hemifacial spasm, left.
    G51.33Clonic hemifacial spasm, bilateral.
    G51.39Clonic hemifacial spasm, unspecified.
    G80.0Spastic quadriplegic cerebral palsy.
    G80.1Spastic diplegic cerebral palsy.
    G80.2Spastic hemiplegic cerebral palsy.
    G80.3Athetoid cerebral palsy.
    G80.4Ataxic cerebral palsy.
    G80.8Other cerebral palsy.
    G80.9Cerebral palsy, unspecified.
    1–10 of 25
    1/3
    Covered ICD-10 Codes (continued)ICD-10Covered
    G83.11Monoplegia of lower limb affecting right dominant side.
    G83.12Monoplegia of lower limb affecting left dominant side.
    G83.13Monoplegia of lower limb affecting right nondominant side.
    G83.14Monoplegia of lower limb affecting left nondominant side.
    G83.20Monoplegia of upper limb affecting unspecified side.
    G83.21Monoplegia of upper limb affecting right dominant side.
    G83.22Monoplegia of upper limb affecting left dominant side.
    G83.23Monoplegia of upper limb affecting right nondominant side.
    G83.24Monoplegia of upper limb affecting left nondominant side.
    G83.4Cauda equina syndrome.
    1–10 of 22
    1/3
    Covered ICD-10 Diagnosis CodesICD-10Covered
    I69.051Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side
    I69.052Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side
    I69.053Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
    I69.054Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
    I69.059Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting unspecified side
    I69.131Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side
    I69.132Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side
    I69.133Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
    I69.134Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
    I69.139Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting unspecified site
    1–10 of 97
    1/10
    Per‑# days limits (examples)
    Examples of per‑# days limits (HCPCS units)Blepharospasm: 200 units / 84 days; Cervical dystonia: 300 units / 84 days; Strabismus: 100 units / 84 days; Esophageal achalasia: 100 units / 168 days; Upper/Lower limb spasticity: 400 units / 84 days; Chronic migraine: 200 units / 84 days; Severe primary axillary hyperhidrosis: 100 units / 112 days; Sialorrhea: 100 units / 84 days; Neurogenic bladder/detrusor overactivity: 200 units / 84 days; Overactive bladder: 100 units / 84 days; Chronic anal fissures: 100 units / 84 days; Palmar hyperhidrosis: 200 units / 168 days; Laryngeal dystonia: 100 units / 84 days; Hemifacial spasms: 100 units / 84 days; Oromandibular dystonia: 200 units / 84 days; Ventral hernia: 500 units / N/A; Temporomandibular disorders: 200 units / 84 days
    Per‑indication days limits — summaryPer‑# days limits vary by indication (examples above show 84, 112, 168 days or N/A for ventral hernia)
    NotesDays limits correspond to the 'Per # days' column tied to HCPCS billable units in the policy; use indication‑specific pairing when authorizing units for a course of therapy.

    What Providers Must Do

    Prior Authorization

    Prior authorization validity periods

    Initial prior authorizations are valid for 6 months (180 days). Renewals are generally valid for 12 months (365 days) unless an indication specifies a different renewal interval. Exceptions: ventral hernia authorizations may NOT be renewed; strabismus, esophageal achalasia, temporomandibular disorders, and chronic anal fissures may be renewed every 6 months (180 days).

    Prior Authorization

    Evidence required for prior authorization renewal

    Renewal requests must document that the member continues to meet the universal and indication-specific criteria, that the duration of the prior authorization has not been exceeded, and that there is absence of unacceptable toxicity. The renewal must also include evidence of disease response as specified for the treated indication.

    Clinical Background and Scope

    OnabotulinumtoxinA (Botox) is administered by intramuscular, intradetrusor, or intradermal injection for a broad range of neurologic, muscular, and dermatologic conditions. Typical clinical uses cited in the policy include treatment of focal dystonias and spasm disorders (e.g., blepharospasm, cervical dystonia, hemifacial spasm), management of spasticity (upper and lower limb), symptomatic treatment for hyperhidrosis, prophylaxis for chronic migraine, treatment of sialorrhea, and intradetrusor injections for neurogenic detrusor overactivity/overactive bladder, among other indications.

    Definitions and Key Terms

    Chronic migraine definition
    DefinitionChronic migraine = 15 or more headache days per month for >3 months
    Migraine-feature daysAt least 8 days per month for >3 months must have features consistent with migraine or respond to triptans/ergot derivatives
    Documentation requirementBaseline disease severity should be assessed with an objective tool (e.g., HIT-6, MHD, MIDAS, MPFID)
    Detrusor overactivity (neurogenic) definition
    DefinitionDetrusor overactivity associated with neurologic condition = urinary incontinence due to detrusor overactivity confirmed by urodynamic testing
    Age requirementMember is at least 5 years of age for this indication

    Initial Therapy Requirements

    Renewal and Continuation Requirements

    Prior Trials and Step Requirements

    IndicationRequired prior trial(s) before BotoxMinimum duration of prior trial
    Severe Primary Axillary HyperhidrosisTrial and failure of a topical agent (e.g., 20% aluminum chloride, glycopyrronium, aluminum zirconium trichlorohydrate, sofpironium, etc.)≥1 month
    Severe Palmar HyperhidrosisTrial and failure of a topical agent AND failure of iontophoresisTopical: ≥1 month; Iontophoresis: prior failure (duration per prior therapy)
    Chronic Anal FissureOther causes ruled out AND failed non‑pharmacologic supportive measures AND failed conventional pharmacologic therapy (e.g., oral/topical nifedipine, diltiazem, topical nitroglycerin, bethanechol)Pharmacologic: ≥1 month; supportive measures: attempted prior to drug therapy
    Temporomandibular Disorders (TMD)Failed conventional noninvasive therapy (e.g., cognitive behavioral therapy, pharmacotherapy, physical therapy, occlusal devices)3 months
    IndicationRequired prior trial(s) before BotoxMinimum duration of prior trial
    Incontinence due to Detrusor Overactivity (neurogenic)Failed trial of two medications from antimuscarinic or beta‑adrenergic classes (e.g., darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium, mirabegron, vibegron)Each medication: ≥1 month
    Overactive Bladder (OAB)Failed trial of two medications from antimuscarinic or beta‑adrenergic classesEach medication: ≥1 month
    Chronic Migraine (prophylaxis)Documentation of baseline disease severity and use of prophylactic modalities; policy requires assessment and prior use of prophylactic interventions (objective tool documentation required) before initiationNot specified as fixed duration in policy; clinical documentation of prior prophylactic modality use required
    Upper/Lower Limb SpasticityConservative measures and prior therapies per clinical judgment; dosing tailored to individual — policy emphasizes individualized prior management before BotoxNot specified (treatment tailored); re‑treatment intervals noted (≥12 weeks)
    Summary notePolicy guidance
    No uniform step‑therapy sequence specified across indications in the policyPolicy does not mandate explicit multi‑step sequencing; instead, authorization requires documented failure of indication‑specific conservative or pharmacologic therapies where listed, and dosing/re‑treatment must follow the indication‑specific recommendations (e.g., re‑treat no sooner than 12 weeks; adult cumulative dose ≤400 Units per 12 weeks).

    Quantity Limits and Dose Caps

    onabotulinumtoxinA (Botox)
    HCPCS units vary by indicationUnits assigned by indication (e.g., Chronic Migraine = 200 HCPCS units; Neurogenic Detrusor Overactivity = 200 HCPCS units; Upper/Lower Limb Spasticity = 400 HCPCS units)
    Billing codeUse J0585 - Injection, onabotulinumtoxinA, 1 unit (1 billable unit = 1 unit)
    Vial NDCsBotox 100 unit NDC = 00023-1145-xx; Botox 200 unit NDC = 00023-3921-xx
    Botox (onabotulinumtoxinA) — adult maximum
    Adult 12-week capMaximum cumulative adult dose noted as 400 Units in a 3-month (12-week) interval (unless otherwise specified)
    Per-indication maximaSome indications have specific per-dose/unit assignments (see HCPCS unit table) but cumulative cap applies across one or more indications

    Administration Settings

    Note

    Office administration by indication; pediatric localization recommended

    Administer Botox per the indication-specific route and setting (intramuscular, intradetrusor, intradermal, intraparotid). For pediatric procedures, use recommended localization techniques (EMG, nerve stimulation, or ultrasound) and follow the pediatric dosing and administration guidance.

    References, Appendices, and Supporting Materials

    The policy cites multiple guideline, consensus, and review sources supporting chronic migraine and other indications. Representative references include the American Headache Society position statements and consensus documents (see items such as Schwedt TJ. BMJ 2014; American Headache Society statements), ASGE and ACG clinical guidelines for achalasia, and a range of specialty reviews and guideline sources listed in the References section (see the policy’s Reference list for full citations).

    Appendix 1 of the policy contains the covered ICD-10 diagnosis codes referenced in the coding section. When submitting claims or selecting diagnosis codes in the coding tables, use one of the ICD‑10 codes listed in Appendix 1 (the Appendix spans multiple pages and provides the complete set of covered diagnosis codes). See Appendix 1 for the full cross‑reference.

    The policy includes a Non‑Quantitative Treatment Limitations (NQTL) factor checklist in Appendix A that documents considerations used to design prior authorization requirements (indication, safety/efficacy, cost, etc.). This checklist and its conclusions are available in Appendix A and should be consulted for NQTL rationale and how PA criteria were applied.

    Policy Summary
    PayerViva Health
    PolicyBotox (onabotulinumtoxinA) — Coverage Criteria
    Policy CodePolicy IC-0238
    Change TypeNo material clinical or coverage changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization specifying HCPCS J0585 units, document indication-specific dosing and objective baseline/response measures, and ensure absence of contraindications before administration.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes, Units, and Diagnosis CodesWhat Providers Must DoClinical Background and ScopeDefinitions and Key TermsInitial Therapy RequirementsRenewal and Continuation RequirementsPrior Trials and Step RequirementsQuantity Limits and Dose CapsAdministration SettingsReferences, Appendices, and Supporting Materials
    Adult cumulative dose per 12 weeks
    Adult cumulative dose cap (12 weeks)Maximum cumulative dose in adults should not exceed 400 Units in a 3‑month (12‑week) interval unless an indication specifies otherwise (e.g., Ventral Hernia).
    Rationale/sourcePolicy dosing section states the 400 Units per 3‑month (12‑week) adult cumulative limit and calls out Ventral Hernia as an exception.
    Re‑treatment interval interactionRe‑treatment should generally occur no sooner than 12 weeks from the prior injection, so 400 Units applies across that 12‑week window.
    Pediatric cumulative dose per 12 weeks
    Pediatric cumulative dose cap (12 weeks)Total pediatric dose in a 3‑month (12‑week) interval must not exceed the lower of 10 Units/kg body weight or 340 Units.
    Example pediatric limitsUpper limb: max 6 U/kg or 200 U per session (recommended 3–6 U/kg); Lower limb: 4–8 U/kg, per‑session caps apply; combined limbs use the 10 U/kg or 340 U per 12 weeks rule.
    Guidance sourcePolicy Dosage/Administration pediatric dosing and cumulative‑dose language (per‑session and 3‑month cumulative caps).
    NQTL considerations (Appendix A)
    NQTL factors considered for PAIndication considered for PA: Yes (NQTL checklist) — indication is a factor in prior authorization decisions.
    Safety/efficacy considered for PASafety and efficacy considered for PA: Yes (NQTL checklist) — safety/efficacy are applied when designing prior authorization rules.
    Cost considered for PACost of drug considered for PA: Yes (NQTL checklist) — drug cost factored into PA design.
    Other NQTL itemsPotential for misuse/abuse: No — PA not prioritized for misuse/abuse per checklist; utilization review and prior authorization are examples of NQTLs.
    Billing Rule

    Include HCPCS J0585 and vial NDC on claim

    Claims must report HCPCS J0585 (onabotulinumtoxinA, 1 unit) and list vial NDC(s) that correspond to the Botox preparation used (e.g., 00023-1145-xx for 100-unit vial; 00023-3921-xx for 200-unit vial). Units billed must be consistent with the indicated dosing and vial sizes.

    Prior Authorization

    PA may be required per NQTL considerations

    Prior authorization may be applied based on factors in the policy's NQTL checklist; the plan considered indication, safety/efficacy, and drug cost when determining PA applicability.

    Note

    Follow Medicare NCD/LCD/LCA requirements where applicable

    When Medicare members are involved, comply with applicable Medicare Part B coverage determinations (NCDs/LCDs) and Local Coverage Articles; these federal policies may govern coverage and claims payment where applicable.

    Step Therapy

    Hyperhidrosis: required prior topical and iontophoresis trials

    For severe primary axillary and palmar hyperhidrosis, document a trial and failure of at least a 1-month topical agent (e.g., 20% aluminum chloride). For palmar hyperhidrosis specifically, also document failure of iontophoresis. Additionally document medical complications or significant impact on activities of daily living as required.

    Step Therapy

    Document required prior trials for specific indications

    Before Botox is authorized for certain indications, document required prior trials: e.g., for chronic anal fissure rule out other causes and document failure of nonpharmacologic supportive measures and a ≥1 month trial of conventional pharmacologic therapy; for TMD document failure of a 3‑month trial of conventional noninvasive therapy.

    Step Therapy

    No universal step-therapy sequence required

    The policy does not impose a universal step-therapy sequence; follow the indication-specific prior trial and dosing guidance provided in the policy rather than a mandated multi-step sequence.

    Note

    NQTL checklist drives PA considerations (indication, cost)

    The NQTL checklist explicitly noted that indication and cost were considered when applying prior authorization; use this checklist as the basis for PA consideration.

    Note

    Inventory item (no label in excerpt)

    This callout references an inventory item without content in the provided excerpt; consult the full policy for any missing or organization-specific instructions tied to this item.

    Documentation Required

    Chronic migraine: baseline objective severity and prophylaxis documentation

    For chronic migraine prophylaxis, include a baseline disease severity assessment using an objective tool (e.g., HIT-6, monthly headache days [MHD], MIDAS, MPFID) and document that prophylactic modalities are being used and other causes of headache have been ruled out.

    Documentation Required

    Required documentation to support renewals

    Renewal documentation must show continued fulfillment of universal and indication-specific criteria, absence of unacceptable toxicity, that the authorization duration has not been exceeded, and evidence of disease response appropriate to the treated indication.

    Documentation Required

    Document dosing, target muscles, total units, and re‑treatment timing

    Document the administration details: indication-specific dosing, total units administered, muscles or sites targeted, and adherence to minimum re‑treatment intervals and cumulative dose limits (e.g., per-indication doses and 12‑week cumulative caps).

    Billing Rule

    Reference CMS LCAs for billing and coding guidance

    Follow the listed CMS Local Coverage Articles and Local Coverage Articles/LCAs referenced in the policy for billing and coding guidance when submitting claims for botulinum toxin injections.

    Billing Rule

    Use a covered Appendix 1 ICD-10 code on the claim

    Include an appropriate ICD-10 diagnosis code from Appendix 1 on the claim to support medical necessity; use one of the covered codes listed in the policy's Appendix 1.

    Denial Risk

    Avoid treatment when FDA‑labeled contraindications or concurrent botulinum toxin exist

    Do not submit requests for members with FDA-labeled contraindications: hypersensitivity to botulinum toxin or components, active infection at the injection site, or for intradetrusor injections in members with current UTI or urinary retention. Also avoid concurrent use with another botulinum toxin.

    Denial Risk

    Renewal denials for toxicity, lack of criteria, or exceeded duration

    Renewal may be denied if there is unacceptable toxicity from the drug or if the member no longer meets the universal or indication-specific criteria or the authorization duration has been exceeded.

    Denial Risk

    Dose and interval limits enforced; exceedance risks denial

    Coverage may be limited or denied if cumulative dosing limits or minimum re‑treatment intervals are violated—for adults, do not exceed 400 Units in any 12‑week interval (unless otherwise specified); pediatric caps apply (lower of 10 U/kg or 340 U per 12 weeks).

    Prior Authorization

    PA considerations: indication, safety/efficacy, cost

    Per the NQTL checklist and policy text, prior authorization may be considered based on the treated indication, safety/efficacy concerns, and drug cost.

    Billing Rule

    Dual coding: include required secondary G or I code with primary G/M codes

    When billing primary G or M codes, include the required secondary G or I code; failure to include the secondary code can render the primary code non‑payable and risk claim denial.

    Pre-treatment requirementNo current untreated UTI and failed ≥1 month trial of two medications from antimuscarinic or beta-adrenergic classes
    Unacceptable toxicity
    Scope of unacceptable toxicityClinically significant adverse effects including symptoms of toxin spread and clinically significant effects with pre-existing neuromuscular disorders (e.g., asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria)
    Severe reactions listedSevere hypersensitivity (anaphylaxis, serum sickness, urticaria, soft tissue edema, dyspnea) and severe pulmonary effects are examples
    Other serious eventsCorneal exposure/ulceration, retrobulbar hemorrhage, autonomic dysreflexia, urinary complications, and severe infections are cited as unacceptable toxicity examples
    Units (Botox)
    Botox units are product-specificUnits of Botox are specific to the preparation and assay method utilized and are not interchangeable with other botulinum toxin products
    No conversionUnits cannot be compared to or converted into units of any other botulinum toxin products
    Billing implicationHCPCS billing and dosing must reflect onabotulinumtoxinA (Botox) unit assignments as provided
    Re-treatment interval
    Standard intervalUnless otherwise stated for a specific indication, re-treatment should occur no sooner than 12 weeks from the prior injection
    Indication-specific exceptionsSome indications specify different intervals (e.g., axillary hyperhidrosis intradermal every 16 weeks; palmar/plantar hyperhidrosis every 24 weeks) — see indication dosing
    Documentation neededProviders should document adherence to re-treatment intervals as part of administration records
    Chronic migraine and other indications
    Guideline sourcesReferences include American Headache Society, IHS, ACG, ASGE, AGA, EFNS and multiple reviews supporting chronic migraine and other indications
    Selected citationsExamples: Schwedt TJ. Chronic Migraine. BMJ. 2014; AHS position statements; IHS/Cephalalgia 2024/2025 updates
    Reviews and guidelinesAdditional citations cover hyperhidrosis, spasticity, dystonia, neurogenic bladder, anal fissure, and ventral hernia adjunct use
    Re-treatment timing reminderRe-treat no sooner than every 12 weeks in typical cases
    Botox (onabotulinumtoxinA) — pediatric cap
    Pediatric cap (12-week interval)Maximum pediatric cumulative dose = lower of 10 Units/kg body weight or 340 Units per 3-month (12-week) interval
    Upper/lower limb guidanceWhen treating both lower limbs or upper and lower limbs in combination, cumulative dose should not exceed min(10 U/kg, 340 U) per 3 months
    Session maxima examplesPediatric upper limb session max often cited as 6 U/kg or 200 U (whichever is lower) for isolated sessions